Background-Gemcitabine is a novel nucleoside analogue which has shown promising results in most solid tumors; like the arabinosylcytosine analogue, gemcitabine may be an active drug in lymphoproliferative malignancies. We tested it in pretreated peripheral T-cell lymphoma patients with isolated skin involvement.
Introduction
In contrast to other non-Hodgkin's lymphomas where major therapeutic advances have been made, peripheral T-cell neoplasms remain, as originally described in the R.E.A.L. Classification [1] , a particular subset of diseases for which there are no curative conventional systemic therapies. In particular, for advanced-stage mycosis fungoides (MF) and peripheral T-cell lymphoma unspecified (PTCLU) with exclusive skin involvement, there is a pressing need to evaluate new agents, because conventional forms of treatment including chemotherapy, radiotherapy, and the combined modality approach do not appear particularly effective [2] [3] [4] .
Gemcitabine (2',2'-difluorodeoxycytidine), a new nucleoside analog, exerts its antitumor activity via multiple mechanisms [5] . It has been found in preclinical and clinical studies [6] to have a broad spectrum of activity.
In a prospective mono-institutional phase II study, we administered gemcitabine intravenously in 13 pretreated patients with MFand PTCLU in an ambulatory setting.
Patients and methods

Patient population
Between May and November 1997, having given their informed consent. 13 patients, five of them with MF and eight with PTCLU, were treated with gemcitabine. Eight were males and five females with a mean age of 55 years (range 25-73), and all of them had been previously treated by at least two chemotherapeutic and/or radiotherapeutic approaches. The median number of pretreatments was 3 (range 2-5), as listed in Table 1 . Patients were required to have diagnoses of MF or PTCLU that had relapsed or progressed following at least two conventional therapeutic attempts. Patients were selected according to strict criteria: isolated cutaneous involvement for at least six months, and negative results from an exhaustive study of possible spread. Lesions were either limited to a single cutaneous region or were disseminated, involving at least two nonadjacent regions. Patients with MF were in stages IIB-III of theTNM classification of cutaneous T-cell lymphoma [7] ; patients with PTCLU were in stage IV for diffuse skin involvement of the Ann Arbor staging system [8] , The diagnoses were confirmed histologically according to the R.E.A.L. Classification [1] , and an immunohistochemical study was performed. Further eligibility requirements were a WHO performance status of at least $ 2, a time lapse of eight weeks since prior chemotherapy or radiation, age > 18 years, and normal renal, hepatic, and cardiac function Informed consent was obtained from all patients in accordance with the ethics policy of the institute; the study was performed in accord with the Helsinki declaration
Pretreatment investigations
The extent of disease was determined by complete skin examination, CT scanning of the chest, abdomen and pelvis, and bone marrow aspiration and trephine biopsy. All patients presented disease only on the skin. At the time of entry into the study, patients were completely evaluated for the extent of their skin lesions.
Drug therapy
Gemcitabine hydrochlonde (Gemzar; Eli-Lilly) was supplied as a lyophilized powder. The drug was diluted in normal saline and administered intravenously over 30 minutes. Gemcitabine was given on days 1, 8, and 15 of a 28-day schedule at the dose of 1200 mg/m 2 for a total of three cycles. All cycles were delivered on an outpatient basis.
Efficacy and safety evaluation
Tumor response was determined by measuring the reduction of skin lesions in both MF and PTCLU patients. Response was evaluated according to the following criteria: complete response (CR): complete disappearance of skin lesions: partial response (PR), reduction of more than 50% in the overall skin involvement; no response (NR): no change or progression of skin lesions.
Patients were evaluated by weekly history and physical examination, complete blood counts, chemistry profiles, and urine analyses. All signs, symptoms or laboratory abnormalities were assessed in accord with WHO criteria for toxicities.
Results
Response to therapy
The overall response rate in all 13 patients was 69%, one of 13 (8%) CR and eight of 13 (61%) PR, which included 80% (four of five) in MF patients and 63% (five of eight) in PTCLU patients. There was one CR in a patient with PTCLU who had previously been resistant to two lines of conventional chemotherapy. PRs were seen in eight patients: four with MF and four with PTCLU. Four patients (one with MF and three with PTCLU) showed NR. All responses occurred no later than after two courses of gemcitabine. After gemcitabine therapy, patients were observed without further treatment until relapse or progression.
Follow-up duration is currently short (median 11 months, range 6-13 months). All but one of the responding patients have maintained their responses; the CR patient is still disease-free eigth months following cessation of the therapy. The MF patient who showed disease progression three months after discontinuation of treatment again in PR after a new course of gemcitabine.
Toxicity
In general, gemcitabine was extremely well tolerated. Concerning the hematological toxicity, no WHO grade 3 or 4 anemia, neutropenia, or thrombocytopenia was observed. Neutropenia (grades 1 and 2) was observed in three (23%) patients and thrombocytopenia (grades 1 and 2) was observed in one (8%) patient. Drug-related symptomatic toxicity was generally mild: grade 1 fever was relatively common, occurring in five of 13 (39%) patients. There were no infections.
One patient had transient elevated liver enzymes. No nausea/vomiting was recorded. Hair loss was mild to moderate, and none of the patients experienced total alopecia.
Discussion
The prognosis of peripheral T-cell lymphomas, including advanced stage MF and PTCLU with exclusive skin involvement, is generally considered poor [2] [3] [4] . In PTCLU, an extranodal presentation is quite frequent, with diagnostic material deriving from tonsils, soft tissue and, especially, skin, where the histologic picture mimics the tumor phase of MF. In advanced-stage MF, chemotherapy is generally recommended, but few patients obtain a long-lasting remission [2] .
Gemcitabine is a novel nucleoside analog with a broad spectrum of antitumor activity (advanced pancreatic cancer, non-small-cell lung, ovarian, breast, and bladder cancers). In hematologic fields, gemcitabine has been shown to be active in heavily pretreated Hodgkin's disease patients [9] .
In the present study of a mixed group of previously treated patients, we have shown that gemcitabine effectively induces remission in pretreated patients with peripheral T-cell lymphoma, particularly those with PTCLU. These preliminary data indicate that gemcitabine is associated with a significant high overall response rate (69%). In this study, gemcitabine-treated patients had a higher overall response rate compared with literature data on MF patients treated with other purine analogs such as fludarabine [10] . In addition, all therapy was given in an outpatient setting, and related toxicity was very modest. There was no organ toxicity. Standard antiemetics were not used and no cumulative toxicity patterns were observed.
Its modest toxicity profile and easy schedule of administration make gemcitabine an ideal agent for consideration in the development of chemotherapy regimens. In 1353 particular, it would be interesting to gain a better understanding of the role of different nucleoside analogs (fludarabine and gemcitabine) in modulating the entry route into DNA [11, 12] .
Larger trials will be necessary, and are currently being performed, to further explore the therapeutic potential of gemcitabine for patients with peripheral T-cell lymphomas with isolated skin involvement, as well as for other types of lymphoma.
